The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announces new appointments of cancer researchers to lead committees in its expansive scientific program. ECOG-ACRIN is at the forefront of ...
With funding, resources, and collaboration, experts can improve their analysis and help patients. How are ECOG-ACRIN and Caris Life Sciences teaming up to fight cancer? Their recent announcement will ...
Annual Meeting & Exposition provides insights into the prognostic utility of geriatric assessment tools and their role in ...
19 天on MSN
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...
The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...
Patients were excluded from the trial if they had active or suspected autoimmune disease, an allogeneic stem cell transplant ...
来自MSN18 天
High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients ...Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission by the ECOG-ACRIN Cancer Research Group ...
These findings support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with "good-risk" DCIS who opt to skip RT. Read on!
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈